Latest Pathology News

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

Invex Therapeutics reports encouraging results from its collaboration with Tessara Therapeutics, showing Exenatide’s potential to improve neuronal survival in a 3D human brain model of Alzheimer's disease. The company maintains a stable cash position while exploring new neurological partnerships.